AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05642715
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants, regardless of study arm, will be offered: A 12-week course of varenicline dosed according to product label.
Trial: NCT05287568
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with \> 1,000-fold higher affinity to BCL-2 (Ki \< 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki \> 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
Trial: NCT05287568
Drug: CC-486
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.
Trial: NCT05164848
Drug: JMT101
RxNorm normalized name: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr))
DrugBank: Becotatug (DB19069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.
Trial: NCT05164848
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
Trial: NCT04776044
Drug: ATR-002
RxNorm normalized name: Atr-101 free base
DrugBank: Nevanimibe (DB16254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg tablets for oral intake
Trial: NCT06378138
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive Orelabrutinib orally as per the protocol，once daily for every 28 days as one treatment cycle
Trial: NCT05844436
Drug: Pritelivir
RxNorm normalized name: Pritelivir
DrugBank: Pritelivir (DB11844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive a loading dose of 400 mg (4 x 100 mg tablet) pritelivir on first day followed by continuous dose of 100 mg per day.
Trial: NCT05116787
Drug: BCX9930 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally twice daily
Trial: NCT05406817
Drug: Revumenib
RxNorm normalized name: Revumenib
DrugBank: Revumenib (DB18515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.
Trial: NCT05665361
Drug: Sasanlimab
RxNorm normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sasanlimab will be given (SC on day 1 of every cycle, starting on day 1 (+/- 5 days) of cycle 2).
Trial: NCT05665361
Drug: Palbocicilib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib will be given PO for 21 days of every 28-day cycle, starting on day 1 of cycle 1.
Trial: NCT05159830
Drug: Cannabidiol oral oil
RxNorm normalized name: CANNABIDIOL OIL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Oral oil contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed oral oil.
Trial: NCT06331182
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg) after induction of general anesthesia.
Trial: NCT06331182
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg after induction of general anesthesia.
Trial: NCT06331182
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 29 ml bupivacaine 0.25%
Trial: NCT04928846
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05956041
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg Intravenously
Trial: NCT05956041
Drug: Mogamulizumab
RxNorm normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1mg/kg Intravenously
Trial: NCT05935930
Drug: Propofol 10 MG/ML Injection
RxNorm normalized name: propofol 10 MG/ML Injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion
Trial: NCT05935930
Drug: Sevoflurane Inhalation Liquid
RxNorm normalized name: Sevoflurane Inhalation Liquid
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane inhalation
Trial: NCT05300282
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice).
Trial: NCT05233774
Drug: Allogeneic MSC
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation
Trial: NCT05351073
Drug: NBO
RxNorm normalized name: quinbolone
DrugBank: Quinbolone (DB13484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
Trial: NCT05061706
Drug: Lumateperone
RxNorm normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 42 mg capsules administered orally, once daily.
Trial: NCT00002196
Drug: CI-1012
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06158412
Drug: All-trans Retinoic Acid in combination with the KPD Regimen
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~1. ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~   The last ATRA dose will be given in the evening on the day of carfilzomib administration.~2. Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~3. Pomalidomide 4mg orally daily, d1-21;~4. Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; \>75 years: 20 mg/day.
Trial: NCT05941520
Drug: Acolbifene Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Acolbifene (DB16080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05941520
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05583669
Drug: DS-2325a
RxNorm normalized name: DS-2325a
DrugBank: DS-2325a (DB18134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection (starting dose 300 mg)
Trial: NCT04989621
Drug: Orelabrutinib and Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.
Trial: NCT04989621
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib 150mg po qd
Trial: NCT05589610
Drug: EQ101
RxNorm normalized name: EQ101
DrugBank: EQ101 (DB17396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses
Trial: NCT05202613
Drug: Doravirine
RxNorm normalized name: Doravirine
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
Trial: NCT05024318
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles
Trial: NCT05883540
Drug: Lysergic Acid Diethylamide Tartrate
RxNorm normalized name: diethylamine salicylate
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg p.o.
Trial: NCT05883540
Drug: Lysergic Acid Diethylamide Tartrate
RxNorm normalized name: diethylamine salicylate
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 or 200 μg p.o.
Trial: NCT05326425
Drug: lazertinib(YH25448)
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - lazertinib 240mg(3tablets, 80mg/1tablet), once a day, oral, before disease progression
Trial: NCT04121299
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol 40mg Extended Release Once Daily
Trial: NCT05105958
Drug: Tideglusib
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day per os
Trial: NCT04121299
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 10mg Once Daily
Trial: NCT05145010
Drug: Infigratinib
RxNorm normalized name: INFIGRATINIB
DrugBank: Infigratinib (DB11886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infigratinib minitablets or sprinkle capsules to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
Trial: NCT05145010
Drug: Infigratinib
RxNorm normalized name: INFIGRATINIB
DrugBank: Infigratinib (DB11886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the subjects naïve to Infigratinib will be 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
Trial: NCT04457310
Drug: CVL-562 (PF-06412562) 1 mg
RxNorm normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Trial: NCT04457310
Drug: CVL-562 (PF-06412562) 4 mg
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Trial: NCT04457310
Drug: CVL-562 (PF-06412562) 15 mg
RxNorm normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Trial: NCT04457310
Drug: CVL-562 (PF-06412562) 25 mg
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Trial: NCT06641414
Drug: Lisaftoclax (APG-2575)
RxNorm normalized name: APGA
DrugBank: Lisaftoclax (DB18054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, oral administration.
Trial: NCT06641414
Drug: Azacitidine Injection
RxNorm normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: QD, hypodermic or intravenous injection.
Trial: NCT06642428
Drug: Neoadjuvant therapy + vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
Trial: NCT05814354
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.
Trial: NCT04872270
Drug: Zofran 4Mg Tablet
RxNorm normalized name: Zofran 4mg Tablet
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given postoperatively as standard post-op management
Trial: NCT04684368
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04684368
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04684368
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04684368
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or orally
Trial: NCT04684368
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04924660
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Trial: NCT04987307
Drug: Efavaleukin alfa
RxNorm normalized name: Efavaleukin alfa
DrugBank: Efavaleukin alfa (DB16149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavaleukin alfa will be administered by subcutaneous (SC) injection.
Trial: NCT05699811
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125mg/m2, intravenous infusion every 4-6 weeks
Trial: NCT06568367
Drug: Solriamfetol 150 mg
RxNorm normalized name: solriamfetol 150 MG
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solriamfetol tablets, taken once daily
Trial: NCT05699811
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, intravenous infusion every 4-6 weeks
Trial: NCT05055063
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
Trial: NCT04913311
Drug: Immune Checkpoint Inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive CPI per standard of care
Trial: NCT05384496
Drug: Nivolumab and/or Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination of nivolumab 3mg/kg IV every 3 weeks with ipilimumab 1mg/kg or nivolumab 480mg IV every 4 weeks as monotherapy is considered standard of care for patients with unresectable locally advanced or metastatic mucosal melanoma.
Trial: NCT05384496
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg twice daily
Trial: NCT03186456
Drug: Aspirin Tablet
RxNorm normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Aspirin Tablet, 100 mg/d
Trial: NCT06171659
Drug: FDG radiotracer
RxNorm normalized name: (18F)-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
Trial: NCT06643754
Drug: SHR-3276
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset.~Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage.~Indication Expansion: Indications will be selected to evaluate preliminary efficacy.
Trial: NCT05587296
Drug: Elinzanetant (BAY3427080)
RxNorm normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg elinzanetant orally once daily
Trial: NCT06200207
Drug: Ziltivekimab
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilitivekimab will be administered subcutaneously once-monthly.
Trial: NCT05921760
Drug: Ivosidenib
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ivosidenib taken once daily
Trial: NCT05921760
Drug: Recommended Combination Dose (RCD) of ivosidenib
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The RCD of ivosidenib taken once daily
Trial: NCT05921760
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab taken by intravenous infusion
Trial: NCT05921760
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab taken by intravenous infusion
Trial: NCT05114265
Drug: KUR-101
RxNorm normalized name: KUR-113
DrugBank: KUR-113 (DB18413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of KUR-101
Trial: NCT05347693
Drug: Sodium Zirconium Cyclosilicate (SZC)
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement.~Label text will be translated into local language.
Trial: NCT05557812
Drug: non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies
DrugBank: Eugenol (DB09086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
Trial: NCT06048315
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 3 weeks is a treatment cycle, starting from the first day of each treatment cycle with oral administration of 12mg of arotinib once a day, stopping for one week after taking it for two weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
Trial: NCT06048315
Drug: Penpulimab
RxNorm normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the first day, Pianzumab (200mg intravenous infusion) was administered every 3 weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
Trial: NCT04532047
Drug: Aldurazyme (laronidase)
RxNorm normalized name: laronidase Injection [Aldurazyme]
DrugBank: Laronidase (DB00090)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Enzyme replacement therapy for lysosomal storage diseases
Trial: NCT00002084
Drug: Valacyclovir hydrochloride
RxNorm normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002084
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05052723
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.